Clinical Study on Beta Glucan on Patients with Psoriasis

Phase 3

• Conditions: Health Condition 1: L400- Psoriasis vulgaris

• Registration Number: CTRI/2023/05/053308
• Lead Sponsor: ichi-In Bio Sciences Pvt. Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Males and females at least 18 years of age.

2. Except for plaque psoriasis with or without arthritis, subject is in generally good health.

3. Subject exhibits acutely active at least moderate to severe plaque-type psoriasis ( > 5% body surface area (BSA) involvement).

4. Signed, written informed consent

5. Willing and able to comply with study visits according to protocol for the full study period

Exclusion Criteria

1. Patients with forms of psoriasis other than chronic plaque-type psoriasis or with drug-induced psoriasis

2. Use of an investigational drug within 90 days prior to Day 1.

3. Patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results

4. Patient with any active or chronic infection

5. Pregnancy or risk of pregnancy.

6. Patients who are seropositive for HIV1, HIV2, Hepatitis B Surface Antigen, and Hepatitis C

7. Patients unable to give written informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified